次级结果的测量方法是治疗结束时的病毒学应答、生化应答以及组织学应答和不良反应。
Secondary outcome measures were end of treatment virological response, biochemical response, histological response, and adverse events.
方法：分别有84(89%)和83(88%)位患者获得起始的病毒学应答和生化学应答。
Methods: Initial virological and biochemical responses were obtained in 84 (89%) and in 83 (88%) patients respectively.
在两项试验中，持续的病毒学应答率为79%和80%，相比标准治疗方案，即长效干扰素联合利巴韦林的应答率50%更高。
The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin.
结论对拉米夫定治疗6个月以上而没有达到病毒学完全应答的患者进行YMDD变异检测，有助于及时调整治疗方案。
Conclusion it would be helpful to adjust the therapeutic regimen by testing YMDD mutations in patients who receive lamivudine therapy more than 6 months without complete virologic response.
我们也知道有些初始应答较慢的患者，没有获得快速病毒学应答，但可能在12,16或24周时病毒检测阴性，对于这些患者延长治疗可能会有好处。
We know that slower initial responders, those that don't have a rapid viral response, but maybe become negative by week 12, 16, or 24, that extending therapy may also be of some benefit.
结论治疗前较高的ALT水平，较低的HBVDNA定量值及出现早期病毒学应答是影响拉米夫定治疗慢性乙型肝炎疗效的主要因素。
Conclusions the relatively high ALT level, low HBV DNA ration and early virus response are the major factors that affect the curative effect of lamivudine in treating chronic hepatitis B.
持续病毒学应答可以降低肝硬化和肝病并发症的发生，降低肝癌(肝细胞性癌)和死亡的发生率。
Sustained virologic response can result in decreased cirrhosis and complications of liver disease, decreased rates of liver cancer (hepatocellular carcinoma), and decreased mortality.
持续性病毒学应答的最佳指标是较低的治疗前血清hbvDNA滴度和较高的谷丙转氨酶(ALT)水平。
The best indicators of sustained virologic response are low pre-treatment serum HBV DNA titers and elevated alanine aminotransferase (ALT) levels.
这类患者出现持续病毒学应答(SVR)的机率很高——大概是70%到80%，且无治疗的禁忌症，是非常好的治疗对象。
These patients have a high likelihood of SVR (Sustained Virological Response) - probably 70-80% - and in the absence of any contraindications of therapy they are very good candidates.
恩替卡韦治疗慢性乙型肝炎：大多数的部分病毒学应答初治患者无需剂量调整。
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virological response...
应用三联疗法的患者中，超过70%的患者能够达到持续病毒学应答，同时对难治性基因型患者也能获得很好的疗效。
This will comprise of direct antiviral drugs such as protease inhibitors along with peg-Interferon and ribavirin. This can provide a sustained virological response in over 70% of patients.
病毒学应答无论在治疗期还是随访结束时，应答组与非应答组之间的ALT水平差异均有统计学意义。
Results The differences in ALT baselines between viral responding and non-responding groups were significant at treatment time and at the end of the follow-up period.
病毒学应答无论在治疗期还是随访结束时，应答组与非应答组之间的ALT水平差异均有统计学意义。
Results The differences in ALT baselines between viral responding and non-responding groups were significant at treatment time and at the end of the follow-up period.
应用推荐